CTLA4 and melanoma: Here, we investigated the mechanisms and the immune cells involved in the response to a triple combination therapy including guadecitabine and two ICBs (anti-CTLA-4 and anti-PD-1 mAbs) in a SC and a pseudo-metastatic syngeneic mouse model of melanoma.